GLP‐1, GPR40, and α7‐ACh receptor agonists have effectively attenuated pain hypersensitivity in neuropathic pain, inflammatory pain, bone cancer pain, and diabetic pain through spinal microglial autocrine expression of IL‐10 and subsequent expression of β‐endorphin.30, 32, 33, 34, 35. Here, GLP1R is linked to bone cancer.